成都先导药物开发股份有限公司

成都先导药物开发股份有限公司

四川省成都市四川省成都市双流区（天府国际生物城）慧谷东一路8号C2栋

2012

400至449

50,000,000至54,999,999

成都先导药物开发股份有限公司（上海证券交易所股票代码：688222.SH，股票名称：成都先导）致力于打造国际领先的创新型生物医药企业，总部位于中国成都，在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化，着力打造了国际领先的DNA编码化合物库技术（DEL）平台，并拓展了基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）、基于寡核苷酸的药物研发技术（OBT）和靶向蛋白降解技术（TPD）的核心技术平台；同时，公司正在建设DEL+AI+自动化DMTA（设计-合成-测试-分析）分子优化能力平台，以期加速临床前候选药物发现及优化过程。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式，成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前，公司有多个内部新药项目处于临床及临床前不同阶段。获取更多信息，请致电+86-28-85197385，+1-508-840-9646或访问www.hitgen.com。媒体查询：media@hitgen.com投资者咨询：investors@hitgen.com商务开发：bd@hitgen.comHitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.For media inquiries: media@hitgen.com For investor inquiries: investors@hitgen.comFor business development: bd@hitgen.com

610200

服务商

中国,北美洲,西欧

LNA-A(Bz) phosphoramidite(206055-79-0);LNA-G(dmf) phosphoramidite(N/A);LNA-T phosphoramidite(206055-75-6);LNA-5mC(Bz) phosphoramidite(206055-82-5);N6-Bz-A-(S)-GNA phosphoramidite(851050-24-3);N2-iBu-G-(S)-GNA phosphoramidite(182625-68-9);T-(S)-GNA phosphoramidite(168332-13-6);N4-Ac-C-(S)-GNA phosphoramidite(1159174-80-7);UNA-A(Bz) phosphoramidite(1120329-52-3);UNA-G(iBu) phosphoramidite(1120329-61-4);UNA-U phosphoramidite(1120329-48-7);UNA-C(Ac) phosphoramidite(1120329-56-7);(401813-07-8);TT3-LLN( 1821214-50-9);C12-200(1220890-25-4);invAb phosphoramidite(401813-16-9);TNA-A(Bz) phosphoramidite(325683-93-0);TNA-O6-DPC-G phosphoramidite(325683-97-4);TNA-C phosphoramidite(325683-96-3);TNA-T phosphoramidite(325683-94-1);TNA-G phosphoramidite(NA);Ribavirin phosphoramidite(NA);deoxyribavirin phosphoramidite(NA);Tocopherol phosphoramidite(1772522-16-3);2’OC16-A(Bz) phosphoramidite(2382942-35-8);2’OC16-G(iBu) phosphoramidite(2382942-32-5);2’OC16-U phosphoramidite(2382942-83-6);2’OC16-C(Ac) phosphoramidite(2382942-38-1);dSpacer CE Phosphoramidite(129821-76-7);5-OBz-dC(Bz)Phosphoramidite(197579-70-7);U-(S)-GNA phosphoramidite(494784-15-5);2'-Amino-2'-deoxy-5'-O-DMT-uridine(174221-86-4);sulfamoyloxyethane(4403-49-0);BCN-OH(1263166-90-0);5-HEXYN-1-OL-amidite(1048985-37-0);2-Aminopurine amidite(178925-41-2);2-Aminopurine riboside amidite(151059-65-3);2’OTBS-2,6-diamino-G(ibu)-Phosphoramidite(NA);2’O-MOE-2,6-diamino-G(ibu)-Phosphoramidite(NA);2’OMe-2,6-diamino-G(ibu)-Phosphoramidite(NA);5F-dC- Phosphoramidite(NA);LNA-abasic phosphoramidite(NA);2’OMOE-abasic phosphoramidite(2934665-30-0);5F-2’OTBS-U phosphoramidite(173241-78-6);6-bromohexyl phosphoramidite(956093-29-1);pAmpG(2638447-50-2);pLNAAprG(NA);C6 linker phosphoramidite(NA);C9 linker phosphoramidite(NA);C16 linker phosphoramidite(NA);N(TFA)-linker phosphoramidite(NA)

第二十三届世界制药原料中国展

2025-03-06至2025-07-31

E11D01

Intermediates & Fine Chemicals;CMO & CRO;Biotech